Eosinophil and Anticoagulation in COVID-19 Patients

Bursa Postgraduate Hospital80 enrolled

Overview

Despite prophylactic anticoagulant treatments, thrombotic complications may develop in patients with Coronavirus disease 2019 (COVID-19). This study aimed to evaluate anti-Factor Xa levels to determine the anticoagulant activity of low molecular weight heparin (LMWH) in COVID-19 patients.

Study Type

OBSERVATIONAL

Enrollment

Conditions

COVID-19

Interventions

LMWHDRUG

COVID 19 positive patients anticogulation level, subprophylactic level and prophylactic level

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients older than 18 years, who were diagnosed with COVID-19 and were administered LMWH, * agreed to participate in the study were included Exclusion Criteria: * Patients with previous coagulopathy, * continuous indication of anticoagulant therapy (atrial fibrillation (AF), valve disease), * glomerular filtration rate (GFR) \<30 mL/min or undergoing dialysis, or with known liver dysfunction were excluded from the study.

Locations (1)

Bursa Yüksek İhtisas Hastanesi

Yıldırım, Turkey (Türkiye)

Outcomes

Primary Outcomes

subprophylactic anticogulation level

\<0.2IU/ml

Time frame: 14 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.